Novartis CEO Explains Delay In Telling US FDA About Zolgensma Data Fraud: We Wanted To Understand It First

Novartis is in the process of "exiting" the "small number" of scientists involved in the fraud, CEO Narasimhan says.

Decorin protein
Novartis' Rob Kowalski said the company investigated the zolgensma fraud as prescribed in internal policies. • Source: Shutterstock

More from Cell & Gene Therapies

More from Advanced Technologies